Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review
Description
Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Oxford Biomedica plc (OXB) provides process development and manufacturing services tailored to pharmaceutical and biotech companies in the cell and gene therapy sector. The company specialises in viral vector manufacturing, including lentiviral, AAV, and adenoviral vectors. Notable brands associated with OXB include the Lentivector platform, inAAVate, and AdenoVate. OXB's products and services are utilised by clients in the pharmaceutical and biotechnology industries to develop and scale cell and gene therapy products across various therapeutic areas. Based on this platform, It has a partnership and license agreement with other companies to develop potential gene and cell therapy products. OXB operates globally, targeting markets in the cell and gene therapy sector. The company has a presence in different locations in the UK and in Boston, the US. Oxford Biomedica is headquartered in Oxford, England, United Kingdom.
Oxford BioMedica Plc Key Recent Developments
Oct 30,2025: VVMF Announces Strategic Collaboration With OXB, With View to Licencing AAV and Lentiviral Vector Platforms as First Priority
Oct 27,2025: OXB to Participate in Upcoming Investor Conferences and Events
Oct 20,2025: Oxford BioMedica - Board Change
Oct 13,2025: OXB Acquires FDA-Approved Former Resilience Site in Research Triangle
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Oxford Biomedica plc (OXB) provides process development and manufacturing services tailored to pharmaceutical and biotech companies in the cell and gene therapy sector. The company specialises in viral vector manufacturing, including lentiviral, AAV, and adenoviral vectors. Notable brands associated with OXB include the Lentivector platform, inAAVate, and AdenoVate. OXB's products and services are utilised by clients in the pharmaceutical and biotechnology industries to develop and scale cell and gene therapy products across various therapeutic areas. Based on this platform, It has a partnership and license agreement with other companies to develop potential gene and cell therapy products. OXB operates globally, targeting markets in the cell and gene therapy sector. The company has a presence in different locations in the UK and in Boston, the US. Oxford Biomedica is headquartered in Oxford, England, United Kingdom.
Oxford BioMedica Plc Key Recent Developments
Oct 30,2025: VVMF Announces Strategic Collaboration With OXB, With View to Licencing AAV and Lentiviral Vector Platforms as First Priority
Oct 27,2025: OXB to Participate in Upcoming Investor Conferences and Events
Oct 20,2025: Oxford BioMedica - Board Change
Oct 13,2025: OXB Acquires FDA-Approved Former Resilience Site in Research Triangle
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
59 Pages
- Section 1 - About the Company
- Oxford BioMedica Plc - Key Facts
- Oxford BioMedica Plc - Key Employees
- Oxford BioMedica Plc - Key Employee Biographies
- Oxford BioMedica Plc - Major Products and Services
- Oxford BioMedica Plc - History
- Oxford BioMedica Plc - Company Statement
- Oxford BioMedica Plc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Oxford BioMedica Plc - Business Description
- Geographical Segment: Europe
- Performance
- Geographical Segment: United Kingdom
- Performance
- Geographical Segment: United States
- Performance
- R&D Overview
- Oxford BioMedica Plc - Corporate Strategy
- Oxford BioMedica Plc - SWOT Analysis
- SWOT Analysis - Overview
- Oxford BioMedica Plc - Strengths
- Oxford BioMedica Plc - Weaknesses
- Oxford BioMedica Plc - Opportunities
- Oxford BioMedica Plc - Threats
- Oxford BioMedica Plc - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Oxford BioMedica Plc, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Oct 30, 2025: VVMF Announces Strategic Collaboration With OXB, With View to Licencing AAV and Lentiviral Vector Platforms as First Priority
- Oct 27, 2025: OXB to Participate in Upcoming Investor Conferences and Events
- Oct 20, 2025: Oxford BioMedica - Board Change
- Oct 13, 2025: OXB Acquires FDA-Approved Former Resilience Site in Research Triangle
- Oct 07, 2025: OXB Expands US Footprint With Acquisition of Viral Vector Facility
- Sep 23, 2025: Oxford Biomedica Announces Interim Results for the Six Months Ended 30 June 2025
- Jul 28, 2025: Oxford Biomedica Announces Half Year Trading Update
- Jun 03, 2025: OXB Announces Launch of Innovation and Technology Excellence Board
- May 09, 2025: OXB To Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
- Apr 28, 2025: Oxford Biomedical: Notice of 2025 Annual General Meeting
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Oxford BioMedica Plc, Key Facts
- Oxford BioMedica Plc, Key Employees
- Oxford BioMedica Plc, Key Employee Biographies
- Oxford BioMedica Plc, Major Products and Services
- Oxford BioMedica Plc, History
- Oxford BioMedica Plc, Other Locations
- Oxford BioMedica Plc, Subsidiaries
- Oxford BioMedica Plc, Key Competitors
- Oxford BioMedica Plc, Ratios based on current share price
- Oxford BioMedica Plc, Annual Ratios
- Oxford BioMedica Plc, Annual Ratios (Cont...1)
- Oxford BioMedica Plc, Annual Ratios (Cont...2)
- Oxford BioMedica Plc, Interim Ratios
- Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Oxford BioMedica Plc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Oxford BioMedica Plc, Performance Chart (2020 - 2024)
- Oxford BioMedica Plc, Ratio Charts
- Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

